NLGN4Y

Across TCGA pan-cancer cohorts, NLGN4Y Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated NLGN4Y data layer compared with 24 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher NLGN4Y Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated NLGN4Y expression acts as an unfavorable survival marker.

LUAD, READ, and SARC are the cancer types where NLGN4Y Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	All	0.004	0.835	<.001	18	view →
READ	DFS	Median	III,IV	0.059	0.761	<.001	12	view →
SARC	DFS	Median	All	0.121	0.611	.041	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
COAD	OS	Median	II,III,IV	0.642	0.856	.041	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

NLGN4Y–LUAD (OS)

Open the LUAD breakdown →